Table 3.
PheWAS Hits by Symptom Group. The first and second columns give PheCode symptom groups as defined by the PheWAS catalog and the total number of PheCodes in each group. The other columns give the number of phenome-wide significant hits and the proportion of hits to the total number of PheCodes in each symptom group for each cohort in the primary analysis including the two control cohorts.
|
Phenome-Wide Significant Hitsa, b |
||||||||
|---|---|---|---|---|---|---|---|---|
| Symptom Group | Total PheCodes in Groupc | Overall (n = 44,198) | Mild/Moderate (n = 41,629) | Severe (n = 2,569) | Fully Vaccinated (n = 16,468) | Unvaccinated (n = 25,736) | Negative (n = 160,399) | Flu (n = 1,328) |
| circulatory system | 171 | 73 (43 %) | 58 (34 %) | 36 (21 %) | 51 (30 %) | 45 (26 %) | 121 (71 %) | 1 (1 %) |
| congenital anomalies | 56 | 5 (9 %) | 3 (5 %) | – | – | – | 7 (12 %) | – |
| dermatologic | 95 | 10 (11 %) | 15 (16 %) | 2 (2 %) | 6 (6 %) | 7 (7 %) | 35 (37 %) | – |
| digestive | 162 | 26 (16 %) | 20 (12 %) | 9 (6 %) | 12 (7 %) | 21 (13 %) | 88 (54 %) | – |
| endocrine/metabolic | 169 | 43 (25 %) | 28 (17 %) | 26 (15 %) | 17 (10 %) | 31 (18 %) | 97 (57 %) | – |
| genitourinary | 173 | 27 (16 %) | 21 (12 %) | 3 (2 %) | 15 (9 %) | 16 (9 %) | 71 (41 %) | – |
| hematopoietic | 62 | 13 (21 %) | 7 (11 %) | 9 (15 %) | 5 (8 %) | 10 (16 %) | 31 (50 %) | – |
| infectious diseases | 69 | 16 (23 %) | 8 (12 %) | 8 (12 %) | 10 (14 %) | 7 (10 %) | 33 (48 %) | – |
| injuries & poisonings | 122 | 13 (11 %) | 6 (5 %) | 7 (6 %) | 7 (6 %) | 6 (5 %) | 45 (37 %) | – |
| mental disorders | 76 | 24 (32 %) | 22 (29 %) | 15 (20 %) | 17 (22 %) | 18 (24 %) | 52 (68 %) | – |
| musculoskeletal | 132 | 11 (8 %) | 12 (9 %) | 4 (3 %) | 9 (7 %) | 9 (7 %) | 53 (40 %) | – |
| neoplasms | 141 | 39 (28 %) | 32 (23 %) | 7 (5 %) | 22 (16 %) | 23 (16 %) | 72 (51 %) | – |
| neurological | 85 | 18 (21 %) | 14 (16 %) | 5 (6 %) | 9 (11 %) | 14 (16 %) | 46 (54 %) | – |
| pregnancy complications | 46 | 13 (28 %) | 12 (26 %) | – | 9 (20 %) | 9 (20 %) | 19 (41 %) | – |
| respiratory | 85 | 27 (32 %) | 13 (15 %) | 21 (25 %) | 8 (9 %) | 18 (21 %) | 52 (61 %) | – |
| sense organs | 127 | 8 (6 %) | 9 (7 %) | 1 (1 %) | 5 (4 %) | 4 (3 %) | 24 (19 %) | – |
| symptoms | 46 | 6 (13 %) | 5 (11 %) | 4 (9 %) | 3 (7 %) | 3 (7 %) | 26 (57 %) | – |
a
n (% of total PheCodes in group).
b
According to the Holm-Bonferroni method.
c
Not every available PheCode was evaluated in each PheWAS due to case/control thresholds.